PMID- 23669333
OWN - NLM
STAT- MEDLINE
DCOM- 20140109
LR  - 20220311
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 16
IP  - 4
DP  - 2013 Aug
TI  - Intravenous immunoglobulin products contain specific antibodies to recombinant 
      human tau protein.
PG  - 424-8
LID - S1567-5769(13)00180-X [pii]
LID - 10.1016/j.intimp.2013.04.034 [doi]
AB  - Intravenous immunoglobulin (IVIG) products are prepared from plasma 
      immunoglobulins from healthy donors. Pilot studies suggest that IVIG may 
      stabilize cognitive functioning in patients with mild-to-moderate Alzheimer's 
      disease. This study measured antibodies to recombinant human tau protein in the 
      IVIG products Gammagard (Baxter), Gamunex (Talecris), and Flebogamma (Grifols). 
      Anti-tau antibodies were measured by ELISA, subtracting IVIG's polyvalent binding 
      from its binding to tau-coated wells to calculate specific anti-tau antibody 
      levels. Because polyvalent binding of IVIG products may interfere with ELISA 
      measurement of their specific antibody levels, the percentage of binding of each 
      IVIG product to tau-coated wells that was specific for tau was also determined. 
      Specific anti-tau antibodies were detected in all three IVIG products, with 
      significant differences between these products (p<0.001) even when Flebogamma's 
      anti-tau antibodies were doubled to account for its preparation as a 5% solution 
      vs. 10% solutions for Gammagard and Gamunex (means: Gammagard, 3.1 mug/ml; 
      Gamunex, 2.5 mug/ml; Flebogamma, 1.2 mug/ml). The percentages of each IVIG 
      product's specific binding to tau-coated wells also varied between the various 
      products (p<0.001) and between all pairs of IVIG products (means: Gammagard, 
      73.1%; Flebogamma, 54.5%; Gamunex, 37.4%; p<0.01 for all pairwise comparisons). 
      These findings indicate that IVIG products contain specific anti-tau antibodies. 
      The concentrations of these antibodies and the percentages of specific binding of 
      IVIG to tau-coated wells vary between IVIG products. Further studies are 
      indicated to determine if IVIG also contains antibodies to pathologic forms of 
      tau.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
FAU - Smith, Lynnae M
AU  - Smith LM
AD  - Department of Neurology Research, Beaumont Research Institute, Beaumont Health 
      System, 3811 West Thirteen Mile Road, Royal Oak, MI 48073, USA.
FAU - Coffey, Mary P
AU  - Coffey MP
FAU - Klaver, Andrea C
AU  - Klaver AC
FAU - Loeffler, David A
AU  - Loeffler DA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130510
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Recombinant Proteins)
RN  - 0 (tau Proteins)
SB  - IM
MH  - Antibodies, Monoclonal/*immunology/*isolation & purification
MH  - Blotting, Western
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Immunoglobulins, Intravenous/*chemistry/immunology
MH  - Protein Binding
MH  - Recombinant Proteins
MH  - tau Proteins/genetics/*immunology
EDAT- 2013/05/15 06:00
MHDA- 2014/01/10 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/02/22 00:00 [received]
PHST- 2013/04/12 00:00 [revised]
PHST- 2013/04/23 00:00 [accepted]
PHST- 2013/05/15 06:00 [entrez]
PHST- 2013/05/15 06:00 [pubmed]
PHST- 2014/01/10 06:00 [medline]
AID - S1567-5769(13)00180-X [pii]
AID - 10.1016/j.intimp.2013.04.034 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2013 Aug;16(4):424-8. doi: 10.1016/j.intimp.2013.04.034. 
      Epub 2013 May 10.